Enhancement of activated β1-integrin expression by prostaglandin E2 via EP receptors in isolated human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease

Inflammation Research

Volumn 58, Issue 4, 2009, Pages 224-228

  Kajimoto, M ^a   Ichiyama, T ^a   Ueno, Y ^a   Shiraishi, M ^a   Hasegawa, M ^a   Furukawa, S ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

1 integrin; Coronary artery endothelial cells; Prostaglandin E receptor; Prostaglandin E2

Indexed keywords

BETA1 INTEGRIN; BUTYRIC ACID DERIVATIVE; CINNAMIC ACID DERIVATIVE; E PROSTANOID 1 RECEPTOR; E PROSTANOID 2 RECEPTOR; E PROSTANOID 3 RECEPTOR; E PROSTANOID 4 RECEPTOR; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; ISOPROTEIN;

ANTIGEN EXPRESSION; ARTERY ENDOTHELIUM; ARTICLE; CELL ISOLATION; CORONARY ARTERY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BLOOD; CELL CULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; GENETICS; METABOLISM; PHYSIOLOGY;

ANTIGENS, CD29; CELLS, CULTURED; CORONARY VESSELS; DINOPROSTONE; ENDOTHELIAL CELLS; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROTEIN ISOFORMS; RECEPTORS, PROSTAGLANDIN E;

EID: 62949100532     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-8138-y     Document Type: Article

References (38)

1. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001; 305: 285-98.
2. Dormond O, Rüegg C. Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. Thromb Haemost 2003; 90: 577-85.
3. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997; 100: 37-9.
4. 1 and protein kinase A. J Biol Chem 2000; 275: 33920-8.
5. 2 receptor subtype 2 as a receptor activated by OxPAPC. Circ Res 2006; 98: 642-50.
6. Hillis GS, MacLeod AM. Integrins and disease. Clin Sci 1996; 91: 639-50.
7. Sun M, Opavsky MA, Stewart DJ, Rabinovitch M, Dawood F, Wen WH, et al. Temporal response and localization of integrins β1 and β3 in the heart after myocardial infarction: regulation by cytokines. Circulation 2003; 107: 1046-52.
8. Kawasaki T, Kosaki F, Ogawa S, Shigemitsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-6.
9. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki Disease. Pediatrics 1978; 61: 100-7.
10. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379-85.
11. 2 Level in Kawasaki disease. Prostaglandins Leukot Essent Fatty Acids 1988; 31: 53-7.
12. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-226.
13. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Therapeut 2004; 103: 147-66.
14. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282: 11613-7.
15. 4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005; 280: 29993-30000.
16. 1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053-63.
17. 2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases. Biochem Biophys Res Commun 2005; 338: 1171-8.
18. 1 chain. J Biol Chem 1996; 271: 11067-75.
19. Maruyama T. Therapeutic possibilities of subtype-selective compounds to prostaglandin E2 receptor. Med Sci Dig 2003; 29: 326-9. in Japanese
20. Williams TJ, Peck MJ. Role of prostaglandin-mediated vasodilatation in inflammation. Nature 1977; 270: 530-2.
21. Stenson WF, Parker CW. Prostaglandins, macrophages, and immunity. J immunol 1980; 125: 1-5.
22. Hirose S, Hamashima Y. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome. Eur J Pediatr 1978; 129: 17-27.
23. Sugawara T, Hattori S, Hirose S, Furukawa S, Yabuta K, Shirai T. Immunopathology of the skin lesions of Kawasaki disease. In: Schulman ST, editor. Kawasaki Disease. New York: Alan R. Liss, 1987: 185-92.
24. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease. Circulation 2000; 101: 2935-41.
25. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-κB activation in peripheral blood monocytes/ macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001; 99: 373-7.
26. Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, et al. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating β1 integrin. J Clin Invest 1999; 103: 613-25.
27. Shimizu S, Kuratsuji T, Ojima T, Takahashi E. Plasma fibronectin concentrations in mucocutaneous lymph node syndrome. Arch Dis Child 1986; 61: 72-4.
28. Umezawa T, Matsuo N, Saji T. Treatment of Kawasaki disease using the intravenous aspirin anti-inflammatory effect of salicylate. Acta Paediatr Jpn 1992; 34: 584-8.
29. 1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053-63.
30. Camu F, Van Lersberghe C, Lauwers MH. Cardiovascular risk and benefits of perioperative nonsteroidal anti-inflammatory drug treatment. Drugs 1992; 44: 42-51.
31. 2, and its mechanisms. Prostaglandins 1997; 53: 279-89.
32. Poredos P. Possibilities for clinical use of prostacyclin in vascular disease. Pflugers Arch Eur J Physiol 2000; 440: 137-8.
33. 2 in acute thrombosis. Blood 1979; 54: 684-93.
34. 2 synthesis decreases vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. Life Sci 2005; 78: 22-9.
35. Needleman P. Characterization of the reaction sequence involved in phospholipid labeling and deacylation and prostaglandin synthesis and actions. J Allergy Clin Immunol 1978; 62: 96-102.
36. Witt W, Stürzebecher S, Müller B. Synergistic antiplatelet and antithrombotic effects of a prostacyclin analogue (iloprost) combined with a thromboxane antagonist (sulotroban) in guinea pigs and rats. Thromb Res 1988; 51: 607-16.
37. 2 production in endothelium-intact and -injured aorta of guinea pigs. Jpn J Pharmacol 1994; 66: 471-9.
38. 2 from the skin in vivo in humans after the application of cinnamic aldehyde. J Am Acad Dermatol 2001; 45: 62-7.